Ask AI
ProCE Banner Activity

CAR T-Cell Therapy Updates: Key Highlights From Recent Conferences & Answers to Frequently Asked Questions

Clinical Thought

In this commentary, experts highlight recent progress with CAR T-cell therapies in lymphomas and multiple myeloma discussed at recent summer conferences, emphasizing durable remissions and promising new targets beyond BCMA. Ongoing challenges such as relapse management, treatment sequencing, and the need for innovative approaches like allogeneic and in vivo CAR T-cells are also underscored.

Released: September 30, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Disclosure

Primary Author

Brad Kahl, MD: consultant/advisor/speaker: AbbVie, ADCT, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Lilly, Merck, Pfizer, Roche.

Noopur Raje, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Caribou Biosciences, GlaxoSmithKline, Johnson & Johnson, Moderna, Pfizer, Regeneron, Sanofi.